Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|April 8, 2022

A Patient’s Post-MI Journey

Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.

Episodes in this series

EP. 1 The Burden of ASCVD and Evidence-Based Guidelines

EP. 1 The Burden of ASCVD and Evidence-Based Guidelines

EP. 2 A Patient’s Post-MI Journey

EP. 2 A Patient’s Post-MI Journey

EP. 3 Improving the Care Continuum

EP. 3 Improving the Care Continuum

EP. 4 Residual Cardiovascular Risk

EP. 4 Residual Cardiovascular Risk

EP. 5 Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP. 5 Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP. 6 Finding the Optimal Statin Dose

EP. 6 Finding the Optimal Statin Dose

EP. 7 Therapy Beyond Statins in the Inpatient Setting

EP. 7 Therapy Beyond Statins in the Inpatient Setting

EP. 8 Using Adjunct Therapies in LDL Management

EP. 8 Using Adjunct Therapies in LDL Management

EP. 9 Ensuring Continuity of Care for the ASCVD Patient

EP. 9 Ensuring Continuity of Care for the ASCVD Patient

EP. 10 Unmet Needs in Lipid Management

EP. 10 Unmet Needs in Lipid Management

EP. 11 Defining “Optimal Care” for ASCVD Within Health Systems

EP. 11 Defining “Optimal Care” for ASCVD Within Health Systems

EP. 12 What Does a Multidisciplinary Team Look Like?

EP. 12 What Does a Multidisciplinary Team Look Like?

EP. 13 The Future of LDL Management for Patients With High-Risk ASCVD

EP. 13 The Future of LDL Management for Patients With High-Risk ASCVD

EP. 14 Enhancing Patient Care Through Guideline Adherence

EP. 14 Enhancing Patient Care Through Guideline Adherence

EP. 15 Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP. 15 Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP. 16 Appropriate ASCVD Treatment Outside of Closed Health Systems

EP. 16 Appropriate ASCVD Treatment Outside of Closed Health Systems

EP. 17 Utilizing Quality Metrics in ASCVD

EP. 17 Utilizing Quality Metrics in ASCVD

EP. 18 Improving Patient and Provider Engagement

EP. 18 Improving Patient and Provider Engagement

EP. 19 Treatment Disparities in the Management of ASCVD

EP. 19 Treatment Disparities in the Management of ASCVD

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Julie Kanter | Image Credit: Inherited Blood Disorders

Trial Eligibility Requirements Capture Only a Fraction of Adults With Sickle Cell Disease: Julie Kanter, MD

ByBrooke McCormick,Julie Kanter, MD

June 19th 2026

Fibrosis Belongs at Center of MASH End Points: Zobair M. Younossi, MD

ByLaura Joszt, MA,Zobair M. Younossi, MD

June 19th 2026

Verekitug Could Address Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps: Joseph K. Han, MD

BySabrina McCrear,Joseph K. Han, MD

June 18th 2026

Dr Nitin Jain | Image Credit: UT MD Anderson

Phase 1 UCART22 Trial Shows Promising Activity in R/R B-Cell ALL: Nitin Jain, MD

ByBrooke McCormick,Nitin Jain, MD

June 18th 2026

FDA approval | Image Credit: Tada Images - stock.adobe.com

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

ByBrooke McCormick

June 18th 2026

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Monoclonal Antibodies Had Varying Efficacy in Treating MG

How MCOs Should Be Preparing for the OBBBA's Medicaid Cuts: David Brueggeman, MBA